MACROGENICS, INC. License and Services Revenue (Deprecated 2018-01-31)
MACROGENICS, INC. (MGNX) reported License and Services Revenue (Deprecated 2018-01-31) of $4.50 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-07.
Discontinued › Income Statement › Other Income
us-gaap:LicenseAndServicesRevenue · last filed 2018-05-07
- MACROGENICS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $4.50M, a 252.19% increase year-over-year.
- MACROGENICS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $152.08M, a 3540.04% increase year-over-year.
- MACROGENICS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $1.08M, a 46.57% decline year-over-year.
- MACROGENICS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $1.08M, a 98.62% decline year-over-year.
- MACROGENICS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2017 was $155.52M, a 79.62% increase from fiscal 2016.
- MACROGENICS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2016 was $86.58M, a 12.87% decline from fiscal 2015.
- MACROGENICS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2015 was $99.37M, a 110.24% increase from fiscal 2014.
- MACROGENICS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2014 was $47.26M, a 16.72% decline from fiscal 2013.
| Period end | License and Services Revenue (Deprecated 2018-01-31) 3 month | License and Services Revenue (Deprecated 2018-01-31) 3 month as first filed | License and Services Revenue (Deprecated 2018-01-31) 6 month | License and Services Revenue (Deprecated 2018-01-31) 9 month | License and Services Revenue (Deprecated 2018-01-31) 12 month | License and Services Revenue (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2018-03-31 | $4.50M 10-Q · filed 2018-05-07 | $156.58M derived: sum of 2 quarters · filed 2018-05-07 | $157.66M derived: sum of 3 quarters · filed 2018-05-07 | $158.74M derived: sum of 4 quarters · filed 2018-05-07 | ||
| 2017-12-31 | $152.08M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $153.16M derived: sum of 2 quarters · filed 2018-02-27 | $154.24M derived: sum of 3 quarters · filed 2018-02-27 | $155.52M 10-K · filed 2018-02-27 | ||
| 2017-09-30 | $1.08M 10-Q · filed 2017-11-08 | $2.16M derived: sum of 2 quarters · filed 2017-11-08 | $3.44M 10-Q · filed 2017-11-08 | $7.61M derived: sum of 4 quarters · filed 2018-05-07 | ||
| 2017-06-30 | $1.08M 10-Q · filed 2017-08-02 | $2.36M 10-Q · filed 2017-08-02 | $6.54M derived: sum of 3 quarters · filed 2018-05-07 | $8.55M derived: sum of 4 quarters · filed 2018-05-07 | ||
| 2017-03-31 | $1.28M 10-Q · filed 2018-05-07 | $5.46M derived: sum of 2 quarters · filed 2018-05-07 | $7.47M derived: sum of 3 quarters · filed 2018-05-07 | $85.97M derived: sum of 4 quarters · filed 2018-05-07 | ||
| 2016-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $6.19M derived: sum of 2 quarters · filed 2018-02-27 | $84.69M derived: sum of 3 quarters · filed 2018-02-27 | $86.58M 10-K · filed 2018-02-27 | ||
| 2016-09-30 | $2.01M 10-Q · filed 2017-11-08 | $80.51M derived: sum of 2 quarters · filed 2017-11-08 | $82.40M 10-Q · filed 2017-11-08 | $90.33M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-06-30 | $78.50M 10-Q · filed 2017-08-02 | $80.39M 10-Q · filed 2017-08-02 | $88.31M derived: sum of 3 quarters · filed 2018-02-27 | $103.00M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-03-31 | $1.89M 10-Q · filed 2017-05-03 | $9.82M derived: sum of 2 quarters · filed 2018-02-27 | $24.50M derived: sum of 3 quarters · filed 2018-02-27 | $30.10M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2015-12-31 | $7.92M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $22.61M derived: sum of 2 quarters · filed 2018-02-27 | $28.20M derived: sum of 3 quarters · filed 2018-02-27 | $99.37M 10-K · filed 2018-02-27 | ||
| 2015-09-30 | $14.68M 10-Q · filed 2016-11-02 | $20.28M derived: sum of 2 quarters · filed 2016-11-02 | $91.44M 10-Q · filed 2016-11-02 | $96.82M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-06-30 | $5.60M 10-Q · filed 2016-08-03 | $76.76M 10-Q · filed 2016-08-03 | $82.14M derived: sum of 3 quarters · filed 2017-02-28 | $100.42M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-03-31 | $71.17M 10-Q · filed 2016-05-04 | $76.54M derived: sum of 2 quarters · filed 2017-02-28 | $94.83M derived: sum of 3 quarters · filed 2017-02-28 | $104.03M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2014-12-31 | $5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $23.66M derived: sum of 2 quarters · filed 2017-02-28 | $32.86M derived: sum of 3 quarters · filed 2017-02-28 | $47.26M 10-K · filed 2017-02-28 | ||
| 2014-09-30 | $18.28M 10-Q · filed 2015-11-04 | $27.48M derived: sum of 2 quarters · filed 2015-11-04 | $41.89M 10-Q · filed 2015-11-04 | $56.62M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-06-30 | $9.20M 10-Q · filed 2015-08-05 | $23.60M 10-Q · filed 2015-08-05 | $38.34M derived: sum of 3 quarters · filed 2016-02-29 | $58.45M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-03-31 | $14.40M 10-Q · filed 2015-05-06 | $14.40M 10-Q · filed 2014-05-06 | $29.14M derived: sum of 2 quarters · filed 2016-02-29 | $49.25M derived: sum of 3 quarters · filed 2016-02-29 | $61.09M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2013-12-31 | $14.74M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $34.85M derived: sum of 2 quarters · filed 2016-02-29 | $46.69M derived: sum of 3 quarters · filed 2016-02-29 | $56.75M 10-K · filed 2016-02-29 | $56.75M 10-K · filed 2014-03-20 | |
| 2013-09-30 | $20.11M 10-Q · filed 2014-11-12 | $31.95M derived: sum of 2 quarters · filed 2014-11-12 | $42.02M 10-Q · filed 2014-11-12 | |||
| 2013-06-30 | $11.84M 10-Q · filed 2014-08-05 | $21.91M 10-Q · filed 2014-08-05 | ||||
| 2013-03-31 | $10.07M 10-Q · filed 2014-05-06 | |||||
| 2012-12-31 | $59.65M 10-K · filed 2015-03-03 | $59.65M 10-K · filed 2014-03-20 | ||||
| 2011-12-31 | $47.05M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |